SCHEMBL2549708

SCHEMBL2549708

CC(=O)Nc1cccc(B(O)O)c1C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HPGD P15428 3/20 0.53
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
MAOA P21397 1/20 0.44
KDM4E B2RXH2 4/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
CASP6 P55212 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14817806 0.84 ALDH1A1 (0.65) ALDH1A1HPGDPOLBLMNAMAOA
SCHEMBL521100 0.82 ALDH1A1 (0.59) ALDH1A1HPGDPOLBLMNAMAOA
SCHEMBL29469169 0.82 ALDH1A1 (0.59) ALDH1A1HPGDPOLBLMNAMAOA
SCHEMBL3792891 0.81 ALDH1A1 (0.48) ALDH1A1HPGDPOLBMAOAKDM4E
SCHEMBL3585917 0.80 ALDH1A1 (0.47) ALDH1A1HPGDPOLBMAOAKDM4E
SCHEMBL16634480 0.80 BTK (0.45) ALDH1A1POLBLMNACYP2C19MAPT
SCHEMBL2307143 0.79 ALDH1A1 (0.70) ALDH1A1HPGDPOLBLMNAHSD17B10
SCHEMBL3782804 0.79 ALDH1A1 (0.53) ALDH1A1HPGDPOLBMAOAKDM4E
SCHEMBL30702637 0.79 ALDH1A1 (0.70) ALDH1A1HPGDPOLBLMNAHSD17B10
SCHEMBL15535856 0.77 KDM4E (0.45) ALDH1A1HPGDPOLBMAOAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US claimed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP claimed
CN-114794335-A Novel method for processing blackberry pulp 浙江量品生物科技有限公司 2022-07-29 CN claimed
EP-3344232-B1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY UNIV MCMASTER (CA) 2022-01-26 EP claimed
US-10611908-B2 Micelles for mucoadhesive drug delivery MCMASTER UNIVERSITY (CA) 2020-04-07 US claimed
US-20180265694-A1 Micelles for Mucoadhesive Drug Delivery MCMASTER UNIVERSITY (CA) 2018-09-20 US claimed
EP-3344232-A1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY Mcmaster University (CA) 2018-07-11 EP claimed
WO-2017035656-A1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY MCMASTER UNIVERSITY (CA) 2017-03-09 WO claimed
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US disclosed
US-20230139250-A1 FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF EYEPOINT PHARMACEUTICALS INC (US) 2023-05-04 US disclosed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP disclosed
US-11413242-B2 Formulations of Tie-2 activators and methods of use thereof EyePoint Pharmaceuticals, Inc. (US) 2022-08-16 US disclosed
CN-114794335-A Novel method for processing blackberry pulp 浙江量品生物科技有限公司 2022-07-29 CN disclosed
EP-3344232-B1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY UNIV MCMASTER (CA) 2022-01-26 EP disclosed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 WO disclosed
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 US disclosed
EP-2059516-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (publ) (SE) 2009-05-20 EP disclosed
EP-2020404-A1 Cyanomethyl substituted N-Acyl Tryptamines Bayer Schering Pharma Aktiengesellschaft (DE) 2009-02-04 EP disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11413242-B2 Formulations of Tie-2 activators and methods of use thereof TIE1, TEK, KDR ALDH1A1 3387/4885HPGD 719/4885POLB 3471/4885
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 ALDH1A1 1431/4885HPGD 1612/4885POLB 4633/4885
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors FGFR3, FGFR1, FGFR2 ALDH1A1 1131/4885HPGD 1246/4885POLB 3202/4885
US-20230139250-A1 FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF TIE1, TEK, KDR ALDH1A1 3387/4885HPGD 719/4885POLB 3471/4885
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES EPX, EPCAM, ELANE ALDH1A1 561/4885HPGD 519/4885POLB 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.